SLCO1B3 polymorphisms and clinical outcomes in kidney transplant recipients receiving mycophenolate-Reference-Cited by-同舟云学术

SLCO1B3 polymorphisms and clinical outcomes in kidney transplant recipients receiving mycophenolate

Published:2021-11 Issue:17 Volume:22 Page:1111-1120
ISSN:1462-2416
Container-title:Pharmacogenomics
language:en
Short-container-title:Pharmacogenomics

Author:

Schumacher Lauren¹^ORCID,Fang Fang²^ORCID,Kidwell Kelley M²^ORCID,Shakeel Faisal³^ORCID,Hertz Daniel L³^ORCID,Park Jeong M¹³^ORCID,Pasternak Amy L¹³^ORCID

Affiliation:

1. Department of Pharmacy, Michigan Medicine, Ann Arbor, MI 48109, USA

2. Department of Biostatistics, University of Michigan School of Public Health, Ann Arbor, MI 48109, USA

3. Department of Clinical Pharmacy, University of Michigan College of Pharmacy, Ann Arbor, MI 48109, USA

Abstract

Aim: Determine the influence of SLCO1B3 polymorphisms on outcomes in kidney transplant recipients. Materials & methods: We retrospectively evaluated 181 adult kidney transplant recipients receiving mycophenolate. Outcomes included treated biopsy-proven acute rejection (tBPAR), de novo donor-specific antibody (dnDSA) formation, graft survival, patient survival and mycophenolate-related adverse effects among SLCO1B3 genotypes. Results: The presence of SLCO1B3 variants was not associated with increased risk of tBPAR (HR: 1.45, 95% CI: 0.76–2.74), dnDSA (HR: 0.46, 95% CI: 0.16–1.36) or composite of tBPAR or dnDSA (HR: 1.14, 95% CI: 0.64–2.03). Graft and patient survival were reduced among variant carriers; however, inconsistent findings with the primary analysis suggest these associations were not due to genotype. Adverse effects were similar between groups. Conclusion: Presence of SLCO1B3 polymorphisms were not predictive of rejection or dnDSA in kidney transplant recipients.

Publisher

Future Medicine Ltd

Subject

Pharmacology,Genetics,Molecular Medicine

Link

https://www.futuremedicine.com/doi/pdf/10.2217/pgs-2021-0102

Reference33 articles.

1. OPTN / SRTR 2018 Annual Data Report: Kidney

2. Clinical Pharmacokinetics and Pharmacodynamics of Mycophenolate in Solid Organ Transplant Recipients

3. Pharmacokinetics and Concentration-Control Investigations of Mycophenolic Acid in Adults After Transplantation

4. Clinical Pharmacokinetics of Mycophenolate Mofetil

5. Pharmacogenetic influences on mycophenolate therapy

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. SLCO1B3 T334G polymorphisms and mycophenolate mofetil-related adverse reactions in kidney transplant recipients;Pharmacogenomics;2023-01